Other early phase treatment trials of medications including mGluR5 negative modulators fenobam and AFQ056 [15, 16] and GABA-B agonist arbaclofen [17] targeted to the underlying disorder in FXS, based on work in animal models, have shown promise but are not yet available for clinical use. This evidence concerns the gene GRM5 and fragile X syndrome.